FindTrial
Sign In

Therapeutic efficacy comparison of CART19 and chemotherapy in relapsed/refractory acute lymphocytic leukemia

Therapeutic efficacy comparison of CART19 and chemotherapy in relapsed/refractory acute lymphocytic leukemia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ORN-16008948
Enrollment
Unknown
Registered
2016-08-01
Start date
2015-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute lymphocytic leukemia

Interventions

CART19 group and chemotherapy group:different therapy strategies

Sponsors

The First affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 70 Years

Inclusion criteria

Inclusion criteria: All the patients with relapsed/refractory acute lymphocytic leukemia who received CART19 therapy and who received chemotherapy in the recent 2-3 years.

Exclusion criteria

Exclusion criteria: no

Design outcomes

Primary

MeasureTime frame
complete remission;—

Secondary

MeasureTime frame
overall survival;toxicities;—

Countries

China

Contacts

Public ContactHe Huang

The First affiliated Hospital, School of Medicine, Zhejiang University

huanghe@zju.edu.cn+86 13605714822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026